HBK Investments L P boosted its position in shares of Eli Lilly and Co (NYSE:LLY) by 133.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,800 shares of the company’s stock after buying an additional 26,202 shares during the period. HBK Investments L P’s holdings in Eli Lilly and were worth $3,868,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Avestar Capital LLC purchased a new stake in Eli Lilly and during the 4th quarter worth approximately $100,000. Gradient Investments LLC purchased a new stake in Eli Lilly and during the 4th quarter worth approximately $103,000. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and during the 2nd quarter worth approximately $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and during the 2nd quarter worth approximately $129,000. Finally, Front Row Advisors LLC purchased a new stake in Eli Lilly and during the 4th quarter worth approximately $137,000. Institutional investors own 77.58% of the company’s stock.
Eli Lilly and Co (LLY) opened at $80.49 on Friday. The firm has a market capitalization of $86,278.34, a P/E ratio of -402.43, a P/E/G ratio of 1.47 and a beta of 0.28. Eli Lilly and Co has a 52-week low of $73.69 and a 52-week high of $89.09. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.95 earnings per share. analysts anticipate that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the transaction, the insider now directly owns 4,130 shares in the company, valued at $334,901.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Donald A. Zakrowski sold 876 shares of the company’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $77.55, for a total value of $67,933.80. Following the transaction, the insider now owns 4,130 shares in the company, valued at $320,281.50. The disclosure for this sale can be found here. Insiders sold 12,261 shares of company stock valued at $987,485 over the last quarter. 0.20% of the stock is currently owned by company insiders.
A number of research firms have recently issued reports on LLY. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, December 5th. Credit Suisse Group restated a “hold” rating and issued a $80.00 price target on shares of Eli Lilly and in a research report on Friday, February 2nd. TheStreet lowered Eli Lilly and from a “b” rating to a “c” rating in a research report on Monday, March 5th. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and upped their price target for the company from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Jefferies Group set a $93.00 price target on Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. Eli Lilly and presently has a consensus rating of “Hold” and a consensus target price of $93.47.
WARNING: “HBK Investments L P Boosts Holdings in Eli Lilly and Co (LLY)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/17/hbk-investments-l-p-boosts-holdings-in-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.